Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 15/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 14/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 14/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | CFB | P00751 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1717847 | 0.79 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL1723548 | 0.78 | ADRA2B (0.84) | ADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL11903742 | 0.76 | LMNA (0.57) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL4054961 | 0.75 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CADRA1ATRPV1 | |
| SCHEMBL15975257 | 0.75 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL12437176 | 0.74 | HTR1D (0.50) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL2006482 | 0.74 | RAB9A (0.42) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL12437177 | 0.74 | HTR1D (0.50) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL12437171 | 0.74 | RAB9A (0.42) | ADRA2AADRA2BADRA2CADRA1ATAAR1 | |
| SCHEMBL2214929 | 0.74 | HTR1D (0.50) | ADRA2AADRA2BADRA2CADRA1ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178143-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| CN-101855213-A | Therapeutic compounds | ALLERGAN INC | 2010-10-06 | — | — | CN | disclosed |
| EP-2188261-A1 | THERAPEUTIC COMPOUNDS | Allergan, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009023757-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178143-A1 | THERAPEUTIC COMPOUNDS | GOT2, GOT1, ANXA5 | ADRA2A 1550/4885ADRA2B 1943/4885ADRA2C 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.